개 백신 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 백신 유형, 질병 유형, 면역 지속 기간, 투여 경로, 지역별＆경쟁(2021-2031년)

The Global Dog Vaccines Market is projected to expand from USD 1.97 Billion in 2025 to USD 2.88 Billion by 2031, registering a CAGR of 6.53%. These biological preparations are essential for stimulating canine immune systems against specific pathogens like rabies and distemper. Growth is primarily fuelled by heightened awareness of zoonotic diseases, necessitating rigorous preventive care, alongside the trend of pet humanization which increases spending on veterinary services. According to the American Veterinary Medical Association, the United States dog population stood at approximately 89.7 million in 2024, highlighting the vast customer base driving demand.

However, market expansion faces a significant hurdle in the form of complex regulatory frameworks governing product development and approval. Manufacturers must adhere to stringent safety protocols and extensive clinical trials, requiring substantial investment and time. This rigid landscape often delays the release of innovative vaccines and restricts market access across regions with varying compliance standards, effectively slowing the industry's overall growth trajectory.

Market Driver

The trend of pet humanization and rising ownership rates are fundamentally altering the demand for canine immunizations, as owners increasingly view dogs as family members rather than working animals. This shift promotes a willingness to invest in comprehensive preventive healthcare, ensuring rigorous adherence to veterinary protocols to maximize pet longevity. For instance, UK Pet Food's 'Pet Population 2024' report noted that the United Kingdom's dog population reached 13.5 million in March 2024, emphasizing the dense population requiring consistent vaccination for herd immunity.

Simultaneously, the prevalence of zoonotic and infectious diseases serves as a major catalyst for market growth, prompting strict government-led control measures. Authorities are enforcing vaccination mandates to prevent outbreaks of high-mortality pathogens like rabies, which poses risks to humans. The urgency is evident in the Vietnam Government Portal's March 2024 directive following 22 rabies-related deaths early in the year, calling for immediate vaccination coverage. Supporting this industrial scale, Zoetis reported $8.5 billion in total revenue in their February 2024 financial results, reflecting the massive capital backing animal health product development.

Market Challenge

A major barrier to the global dog vaccines market is the intricate regulatory framework governing veterinary biologics, which demands rigorous safety protocols, efficacy testing, and mandatory clinical trials. This fragmented international landscape compels manufacturers to invest heavily in region-specific compliance, diverting resources from research and development. Consequently, these stringent standards create high entry barriers that discourage smaller biotechnology firms and tend to consolidate market power among a few dominant entities.

Additionally, prolonged approval cycles significantly delay the commercialization of new immunization solutions, hindering the industry's response to emerging infectious diseases. Data from the Animal Health Institute in 2024 indicates that the review and approval process for new veterinary biologics takes between five and seven years. This extended timeline limits the speed at which manufacturers can launch products, while the high financial burden of sustaining such development phases reduces the return on investment and limits the frequency of necessary new vaccine introductions.

Market Trends

The rise of Therapeutic Immunotherapies for Canine Oncology marks a shift from purely prophylactic care to curative biological interventions, utilizing autologous tumor antigens or recombinant proteins to target malignancies like osteosarcoma. This approach offers a precision alternative to traditional chemotherapy with reduced systemic toxicity, aiming to extend the lives of patients with aggressive tumors. As reported by Vet Candy in August 2025, clinical trials for a novel EGFR/HER2-targeting vaccine showed a significant improvement in 12-month survival rates, jumping from approximately 35% to 60%.

Concurrently, the adoption of Recombinant and DNA Vaccine Technologies is reshaping manufacturing by replacing conventional inactivated pathogens with genetically engineered vectors. This technology produces highly pure, non-infectious antigens that improve safety and allow for the differentiation of infected from vaccinated animals (DIVA), which is vital for disease eradication. Major players are scaling these platforms, as evidenced by Merck Animal Health's reported full-year sales of $5.9 billion in February 2025, underscoring the strong commercial demand for advanced animal health innovations.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope

In this report, the Global Dog Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccines Market, By Vaccine Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Dog Vaccines Market, By Disease Type

• Canine Distemper
• Canine Infectious Respiratory Disease Complex (CIRDC)
• Canine Parvovirosis/ Parvovirus Disease
• Canine Leptospirosis
• Canine Lyme Disease
• Infectious Canine Hepatitis
• Canine Rabies
• Others

Dog Vaccines Market, By Duration of Immunity

• 1 Year
• 3 Year
• Others

Dog Vaccines Market, By Route of Administration

• Injectables
• Intranasal
• Oral

Dog Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccines Market.

Available Customizations:

Global Dog Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dog Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Others)
  • 5.2.3. By Duration of Immunity (1 Year, 3 Year, Others)
  • 5.2.4. By Route of Administration (Injectables, Intranasal, Oral)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Dog Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Duration of Immunity
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dog Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Duration of Immunity
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Canada Dog Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Duration of Immunity
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Mexico Dog Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Duration of Immunity
      • 6.3.3.2.4. By Route of Administration

7. Europe Dog Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Duration of Immunity
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dog Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Duration of Immunity
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. France Dog Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Duration of Immunity
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Dog Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Duration of Immunity
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Dog Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Duration of Immunity
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Dog Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Duration of Immunity
      • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Dog Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Duration of Immunity
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dog Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Duration of Immunity
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Dog Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Duration of Immunity
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. Japan Dog Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Duration of Immunity
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. South Korea Dog Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Duration of Immunity
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Dog Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Duration of Immunity
      • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Dog Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Duration of Immunity
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dog Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Duration of Immunity
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. UAE Dog Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Duration of Immunity
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. South Africa Dog Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Duration of Immunity
      • 9.3.3.2.4. By Route of Administration

10. South America Dog Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Duration of Immunity
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dog Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Duration of Immunity
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Colombia Dog Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Duration of Immunity
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. Argentina Dog Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Duration of Immunity
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dog Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioveta a.s
• 15.3. Hester Biosciences Limited
• 15.4. Boehringer Ingelheim International GmbH
• 15.5. Brilliant Bio Pharma Private Limited
• 15.6. Heska Corporation
• 15.7. Merck & Co., Inc.
• 15.8. Virbac S.A.
• 15.9. Zendal Group
• 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer